Unicycive Therapeutics, Inc. 8-K

What Happened
On May 12, 2026 Unicycive Therapeutics, Inc. (UNCY) announced its financial results for the quarter ended March 31, 2026 and provided a business update. The company issued a press release covering those results and the update, which was furnished as Exhibit 99.1 to the Form 8-K filed the same day (Item 2.02: Results of Operations and Financial Condition).

Key Details

• Form 8-K filed May 12, 2026, disclosing quarterly results for the period ended March 31, 2026.
• Disclosure furnished (not filed) via a press release included as Exhibit 99.1 to the 8-K.
• Item reported: 2.02 — Results of Operations and Financial Condition.
• The press release contains the company’s Q1 2026 financial results and a business update (details in Exhibit 99.1).

Why It Matters
Quarterly results and business updates provide current information on Unicycive’s revenue, expenses, cash position and development progress — key data points investors use to assess near-term funding needs, operational performance and valuation. Investors should read the Exhibit 99.1 press release for the specific financial figures and any guidance or milestone updates that could influence the stock or financing plans.